HCPLive Network

Fetal NSAID Exposure Not Tied to Persistent Pulmonary Hypertension

MONDAY, Dec. 3 (HealthDay News) -- There appears to be no association between persistent pulmonary hypertension of the newborn (PPHN) and gestational exposure to nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, according to a study published online Dec. 3 in Pediatrics.

To examine the correlation between antenatal exposure to NSAIDs and the risk for PPHN, Linda J. Van Marter, M.D., M.P.H., from Boston Children's Hospital, and colleagues interviewed 377 women whose infants had PPHN, along with 836 control mother/infant pairs matched by hospital and delivery date. Questions included information about prescribed and over-the-counter medications used during pregnancy.

The researchers found that 8.8 percent of infants with PPHN were exposed to any NSAID during the third trimester, compared with 9.6 percent of controls (odds ratio, 0.8; 95 percent confidence interval, 0.5 to 1.3). The odds of PPHN were elevated for infants whose mothers consumed aspirin during the third trimester, but the lower 95 percent confidence interval included the null. Neither ibuprofen use during the third trimester nor non-aspirin NSAIDs at any time during pregnancy was associated with an increased risk of PPHN. There was also no association found between third-trimester acetaminophen exposure and the occurrence of PPHN.

"This large multicenter epidemiologic study of PPHN risk revealed no evidence to support the hypothesis that maternal consumption during pregnancy of NSAIDs overall or ibuprofen in particular is associated with PPHN risk," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Further Reading
Two drugs show promise in the treatment of active systemic juvenile idiopathic arthritis, according to two studies published in the Dec. 20 issue of the New England Journal of Medicine.
The financial burden of caring for patients with chronic low back pain (CLBP) in the United Kingdom is twice that of caring for patients without CLBP, according to a study published in the Jan. 1 issue of Spine.
Fetal nonsteroidal anti-inflammatory drug exposure is not an independent risk factor for spontaneous abortion, according to a study published online Feb. 3 in CMAJ, the journal of the Canadian Medical Association.
Use of triple therapy comprising diuretics and angiotensin converting enzyme inhibitors, or angiotensin receptor blockers, together with nonsteroidal anti-inflammatory drugs is associated with an increased risk of acute kidney injury, particularly in the first 30 days of treatment, according to a study published online Jan. 8 in BMJ.
The US Food and Drug Administration on Friday gave its approval to the first generic version of the pain reliever Celebrex (celecoxib).
Traditional NSAIDs and second-generation NSAIDs (cyclooxygenase-2 inhibitors) are commonly prescribed treatments for a wide range of painful conditions, including acute pain, low back pain, headache, rheumatoid arthritis, and osteoarthritis. However, these medications are also associated with serious gastrointestinal complications and other adverse events.
A retrospective review of records from a large medical database finds that patients with sleep apnea face a substantially higher risk of developing peptic ulcer.
More Reading